These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16869787)

  • 21. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
    Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
    Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
    Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
    Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A
    Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
    Rosell R; Taron M; Reguart N; Isla D; Moran T
    Clin Cancer Res; 2006 Dec; 12(24):7222-31. PubMed ID: 17189393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
    Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
    Hirsch FR; Varella-Garcia M; Cappuzzo F
    Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.
    Miyanaga A; Gemma A; Ando M; Kosaihira S; Noro R; Minegishi Y; Kataoka K; Nara M; Okano T; Miyazawa H; Tanaka T; Yoshimura A; Kobayashi K; Iwanami H; Hagiwara K; Tsuboi E; Kudoh S
    Oncol Rep; 2008 Feb; 19(2):377-83. PubMed ID: 18202784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
    Neal JW; Sequist LV
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):119-26. PubMed ID: 20386533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapies for non-small cell lung cancer.
    Spicer J; Harper P
    Int J Clin Pract; 2005 Sep; 59(9):1055-62. PubMed ID: 16115182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 32. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
    [No Abstract]   [Full Text] [Related]  

  • 33. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 34. Epidermal growth factor receptor signaling in nonsmall cell lung cancer.
    Ganti AK
    Cancer Invest; 2010 Jun; 28(5):515-25. PubMed ID: 20073576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 36. Defining clinically relevant molecular subsets of lung cancer.
    Pao W
    Cancer Chemother Pharmacol; 2006 Nov; 58 Suppl 1():s11-5. PubMed ID: 17093937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC.
    Pallis AG; Syrigos KN
    Lung Cancer; 2013 May; 80(2):120-30. PubMed ID: 23384674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.
    Bencardino K; Manzoni M; Delfanti S; Riccardi A; Danova M; Corazza GR
    Intern Emerg Med; 2007 Mar; 2(1):3-12. PubMed ID: 17551677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.
    Tsao AS; Papadimitrakopoulou V
    Clin Lung Cancer; 2013 Jul; 14(4):311-21. PubMed ID: 23582282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.
    Clark GM; Zborowski DM; Culbertson JL; Whitehead M; Savoie M; Seymour L; Shepherd FA
    J Thorac Oncol; 2006 Oct; 1(8):837-46. PubMed ID: 17409968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.